3,4-dihydroxyphenylacetic acid and Congenital Hypocupremia studies

3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.

Research Excerpts

Excerpt	Relevance	Reference
"In a well-established mouse model of Menkes disease, mottled-brindled (mo-br), we tested whether systemic administration of L-threo-dihydroxyphenylserine (L-DOPS), a drug used successfully to treat autosomal recessive norepinephrine deficiency, would improve brain neurochemical abnormalities and neuropathology."	1.39	L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model. ( Brinster, LR; Donsante, A; Goldstein, DS; Kaler, SG; Sullivan, P, 2013)
"Menkes disease is an X-linked recessive neurodevelopmental disorder resulting from mutation in a copper-transporting ATPase gene."	1.35	Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of menkes disease. ( Goldstein, DS; Holmes, CS; Kaler, SG, 2009)
"Neonatal diagnosis of Menkes disease by plasma neurochemical measurements and early treatment with copper may improve clinical outcomes."	1.35	Neonatal diagnosis and treatment of Menkes disease. ( Donsante, A; Godwin, SC; Goldstein, DS; Holmes, CS; Kaler, SG; Liew, CJ; Patronas, N; Sato, S; Tang, J, 2008)

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Goldstein, DS	3
Holmes, CS	2
Kaler, SG	3
Donsante, A	2
Sullivan, P	1
Brinster, LR	1
Tang, J	1
Godwin, SC	1
Liew, CJ	1
Sato, S	1
Patronas, N	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Early Copper Histidine Therapy in Menkes Disease[NCT00001262]	Phase 1/Phase 2	60 participants (Actual)	Interventional	1990-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate fine motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Gross Motor Development at 36 Mos of Age or at Death (Mos)

Intervention	Other - Months (Mean)
Early	16.200
Late	2.409
Mild	17.667

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate gross motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Language Development at 36 Mos of Age or at Death (Mos)

Intervention	Other - months (Mean)
Early	13.743
Late	2.455
Mild	15.667

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate language development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Personal-Social Development at 36 Mos of Age or at Death (Mos)

Intervention	Other - Months (Mean)
Early	15.800
Late	3.227
Mild	21.000

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate personal-social development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile

Other Studies

3 other studies available for 3,4-dihydroxyphenylacetic acid and Congenital Hypocupremia

Article	Year
Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of menkes disease. Neurochemical research, 2009, Volume: 34, Issue:8 Topics: 3,4-Dihydroxyphenylacetic Acid; Biomarkers; Catechols; Chromatography, High Pressure Liquid; Dopamin	2009
L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model. Annals of neurology, 2013, Volume: 73, Issue:2 Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Triphosphatases; Animals; Antiparkinson Agents; Blood-Brai	2013
Neonatal diagnosis and treatment of Menkes disease. The New England journal of medicine, 2008, Feb-07, Volume: 358, Issue:6 Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Triphosphatases; Biomarkers; Cation Transport Proteins; Co	2008